Our faculty author, co-author and contribute to more than 1500 peer-reviewed scientific publications each year. Find their recent publications below, and filter by division.
Search the faculty directory to find an individual's list of publications.
Publications
Goldberg, J. S., and J. B. Weinberg. “USE OF POLYMER D-LACTIC ACID (PDLA) OR EQUIVALENTS THEREOF TO INHIBIT GROWTH OF CANCER CELLS AND DIAGNOSE CANCER.” USPTO, December 30, 2019.
Ashton, PM, Thanh, LT, Trieu, PH, Van Anh, D, Trinh, NM, Beardsley, J, Kibengo, F, Chierakul, W, Dance, DAB, Rattanavong, S, Davong, V, Hung, LQ, Chau, NVV, Tung, NLN, Chan, AK, Thwaites, GE, Lalloo, DG, Anscombe, C, Nhat, LTH, Perfect, J, Dougan, G, Baker, S, Harris, S, and Day, JN. "Three phylogenetic groups have driven the recent population expansion of Cryptococcus neoformans(Accepted)." Nature Communications 10, no. 1 (December 1, 2019).
Sanyal, Arun, Edgar D. Charles, Brent A. Neuschwander-Tetri, Rohit Loomba, Stephen A. Harrison, Manal F. Abdelmalek, Eric J. Lawitz, et al. “Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial..” Lancet (London, England) 392, no. 10165 (December 2019): 2705–17. https://doi.org/10.1016/s0140-6736(18)31785-9.
PMID
30554783
Ashton, P. M., L. T. Thanh, P. H. Trieu, D. Van Anh, N. M. Trinh, J. Beardsley, F. Kibengo, et al. “Three phylogenetic groups have driven the recent population expansion of Cryptococcus neoformans.” Nature Communications 10, no. 1 (December 1, 2019). https://doi.org/10.1038/s41467-019-10092-5.
Choi, Philip J., Vinca Chow, Farr A. Curlin, and Christopher E. Cox. “Intensive Care Clinicians' Views on the Role of Chaplains..” J Health Care Chaplain 25, no. 3 (July 2019): 89–98. https://doi.org/10.1080/08854726.2018.1538438.
PMID
30518314
Riedel, R., S. Michels, C. Heydt, J. Siemanowski, C. Kobe, A. Bunck, S. Schäfer, et al. “Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.” Lung Cancer 133 (July 1, 2019): 20–22. https://doi.org/10.1016/j.lungcan.2019.05.006.
Emdin, Michele, Alberto Aimo, Aldo Clerico, and James L. Januzzi. “Race/ethnicity and plasma NT-proBNP in black and white individuals: How it matters..” Int J Cardiol 286 (July 1, 2019): 164–65. https://doi.org/10.1016/j.ijcard.2019.03.032.
PMID
30948217
Riedel, R, Michels, S, Heydt, C, Siemanowski, J, Kobe, C, Bunck, A, Schäfer, S, Fischer, RN, Scheffler, M, Abdulla, DSY, Nogová, L, Koleczko, S, Merkelbach-Bruse, S, Büttner, R, and Wolf, J. "Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma(Accepted)." Lung Cancer 133 (July 1, 2019): 20-22.
Riedel, R, Michels, S, Heydt, C, Siemanowski, J, Kobe, C, Bunck, A, Schäfer, S, Fischer, RN, Scheffler, M, Abdulla, DSY, Nogová, L, Koleczko, S, Merkelbach-Bruse, S, Büttner, R, and Wolf, J. "Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma(Accepted)." Lung Cancer 133 (July 1, 2019): 20-22.
Golenbiewski, Jon, and Robert T. Keenan. “Moving the Needle: Improving the Care of the Gout Patient..” Rheumatol Ther 6, no. 2 (June 2019): 179–93. https://doi.org/10.1007/s40744-019-0147-5.
PMID
30826988